Healthcare
Quote through 2026-08-05T13:30:00Z · Stale
Quote synced 2026-08-05T22:36:51.969184Z
Daily bars through 2026-08-03 · Stale
Daily bars synced 2026-08-04T22:41:42.67136Z
Fundamentals through 2025-12-31 · Stale
Fundamentals synced 2026-08-05T21:39:48.519888Z
Forecasts: Stale
Forecasts synced 2026-04-28T01:48:30.601297Z
Ownership through 2025-12-31 · Stale
Ownership synced 2026-08-05T21:39:48.519888Z
Short interest through 2025-12-31 · Stale
Short interest synced 2026-08-05T21:39:48.519888Z
News through 2026-05-21T04:31:35Z · Stale
News synced 2026-05-21T08:50:04.813249Z
Company profile: Delayed
Company profile synced 2026-05-01T03:44:15.887523Z
Regular-session price
Offline$257.59($255.00 after-hours, +0.02%)
+1.04% regular session
1Y Change
+49.30%
Window
Aug 5, 2025 → Aug 4, 2026
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
+1.0%
1M
-1.7%
6M
+8.7%
YTD
+22.9%
1Y
+49.3%
Coverage: 250 bars · Aug 5, 2025 → Aug 4, 2026
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
JNJ is 26.47 pts ahead over the shared 1Y window.
JNJ had 1.83 pts deeper max drawdown than SPY.
JNJ beat SPY in 2 of 2 calendar years shown and trailed in 0.
JNJ
+49.30%
Normalized return
SPY
+22.83%
S&P 500
Excess Return
+26.47 pts
Relative to SPY
JNJ Max Drawdown
-10.96%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for JNJ and SPY.
| Year | JNJ | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +22.94% | +12.67% | +10.27 pts | JNJ |
| 2025 | +21.18% | +9.40% | +11.78 pts | JNJ |
Financials
Annual, quarterly, and TTM views with reported currency, units, source, download, and filing context.
Period
Units
Reported currency
USD
Source
FMP
Last checked
Apr 7, 2026
FY Revenue
$94.2B
+6.0% YoY
FY Net Income
$26.8B
+90.6% YoY
Free Cash Flow
$19.7B
-0.7% YoY
Revenue Growth
+6.0%
EPS Growth
+90.5%
Gross Margin
67.9%
Net Margin
28.5%
Income statement
USD
| Metric | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 78,740M | 79,990M | 85,159M | 88,821M | 94,193M |
| Gross Profit | 55,338M | 55,394M | 58,606M | 61,350M | 68,558M |
| Operating Income | 20,943M | 21,013M | 23,409M | 22,149M | 25,596M |
| EBITDA | 26,751M | 26,605M | 23,320M | 24,781M | 39,904M |
| Net Income | 20,878M | 17,941M | 35,153M | 14,066M | 26,804M |
| EPS (Diluted) | -- | -- | -- | -- | -- |
Balance sheet
USD
| Metric | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14,487M | 12,889M | 21,859M | 24,105M | 19,709M |
| Total Assets | 182,018M | 187,378M | 167,558M | 180,104M | 199,210M |
| Total Liabilities | 107,995M | 110,574M | 98,784M | 108,614M | 117,666M |
| Shareholder Equity | 74,023M | 76,804M | 68,774M | 71,490M | 81,544M |
| Total Debt | 33,751M | 39,642M | 29,332M | 36,634M | 47,933M |
| Net Debt | 19,264M | 26,753M | 7,473M | 12,529M | 28,224M |
Cash flow positioning
2025
Operating Cash Flow
24,530M
+1.1% YoY
Capital Expenditures
4,832M
-9.2% YoY
Free Cash Flow
19,698M
-0.7% YoY
Key ratios
Gross Margin
67.9%
Operating Margin
27.2%
Net Margin
28.5%
ROE
26.3%
Debt / Equity
0.22x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.